Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) CEO Bobak R. Azamian Sells 8,000 Shares

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Get Rating) CEO Bobak R. Azamian sold 8,000 shares of the company’s stock in a transaction dated Wednesday, March 15th. The shares were sold at an average price of $13.79, for a total transaction of $110,320.00. Following the completion of the transaction, the chief executive officer now owns 1,080,536 shares in the company, valued at $14,900,591.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Tarsus Pharmaceuticals Stock Down 5.0 %

Shares of Tarsus Pharmaceuticals stock opened at $12.75 on Friday. The company has a current ratio of 16.40, a quick ratio of 16.40 and a debt-to-equity ratio of 0.10. Tarsus Pharmaceuticals, Inc. has a 12-month low of $10.80 and a 12-month high of $19.66. The firm’s 50-day moving average price is $15.07 and its two-hundred day moving average price is $15.88.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and issued a $40.00 price target on shares of Tarsus Pharmaceuticals in a research note on Wednesday.

Institutional Investors Weigh In On Tarsus Pharmaceuticals

A number of large investors have recently bought and sold shares of TARS. Dimensional Fund Advisors LP grew its stake in Tarsus Pharmaceuticals by 221.0% during the first quarter. Dimensional Fund Advisors LP now owns 28,855 shares of the company’s stock worth $485,000 after buying an additional 19,865 shares in the last quarter. Charles Schwab Investment Management Inc. grew its stake in Tarsus Pharmaceuticals by 3.0% during the first quarter. Charles Schwab Investment Management Inc. now owns 48,583 shares of the company’s stock worth $818,000 after buying an additional 1,402 shares in the last quarter. UBS Group AG grew its stake in Tarsus Pharmaceuticals by 37.0% during the first quarter. UBS Group AG now owns 4,226 shares of the company’s stock worth $71,000 after buying an additional 1,142 shares in the last quarter. Invesco Ltd. lifted its holdings in shares of Tarsus Pharmaceuticals by 17.1% in the first quarter. Invesco Ltd. now owns 27,982 shares of the company’s stock worth $471,000 after acquiring an additional 4,078 shares during the last quarter. Finally, State Street Corp lifted its holdings in shares of Tarsus Pharmaceuticals by 2.4% in the first quarter. State Street Corp now owns 132,883 shares of the company’s stock worth $2,235,000 after acquiring an additional 3,141 shares during the last quarter. 76.82% of the stock is currently owned by institutional investors and hedge funds.

About Tarsus Pharmaceuticals

(Get Rating)

Tarsus Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.